Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ayala Pharmaceuticals's Enterprise Value is $4.71 Mil.
Ayala Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.37 Mil. Therefore, Ayala Pharmaceuticals's EV-to-EBIT ratio for today is -0.19.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Ayala Pharmaceuticals's Enterprise Value is $4.71 Mil.
Ayala Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-24.10 Mil. Therefore, Ayala Pharmaceuticals's EV-to-EBITDA ratio for today is -0.20.
Ayala Pharmaceuticals Enterprise Value Historical Data
The historical data trend for Ayala Pharmaceuticals's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ayala Pharmaceuticals's Enterprise Value
For the Biotechnology subindustry, Ayala Pharmaceuticals's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ayala Pharmaceuticals's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ayala Pharmaceuticals's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Ayala Pharmaceuticals's Enterprise Value falls into.
Ayala Pharmaceuticals Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Ayala Pharmaceuticals's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ayala Pharmaceuticals (OTCPK:ADXS) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Ayala Pharmaceuticals's current Enterprise Value is $4.71 Mil.
Ayala Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.37 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Ayala Pharmaceuticals's EV-to-EBITDA for today is:
Ayala Pharmaceuticals's current Enterprise Value is $4.71 Mil.
Ayala Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-24.10 Mil.
Ayala Pharmaceuticals's current Enterprise Value is $4.71 Mil.
Ayala Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.
Ayala Pharmaceuticals's current Enterprise Value is $4.71 Mil.
Ayala Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-14.18 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ayala Pharmaceuticals Enterprise Value Related Terms
Thank you for viewing the detailed overview of Ayala Pharmaceuticals's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Ayala Pharmaceuticals Inc is a clinical-stage oncology company whose primary clinical assets currently include aspacytarabine (BST-236), a novel proprietary anti-metabolite for first-line treatment in unfit acute myeloid leukemia (AML). BST-236 is a novel prodrug of cytarabine, enabling the delivery of high cytarabine doses with reduced systemic toxicity, creating a potential new backbone for AML combination regimens. It believes that its novel product candidates if approved, have the potential to transform treatment outcomes for patients suffering from solid and hematological cancers. These efforts are primarily focused on the development of ADXS-504, an Lm-based therapy for early-stage prostate cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADXS has been successfully added to your 